Publication | Closed Access

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Chemotherapy Versus PlaceboMedicineFirst-line GefitinibCancer GrowthPathologyBronchial NeoplasmCancer TreatmentOncologyRadiation OncologyLung CancerMolecular OncologyPhase 3